Ano de Publicação: 2014
AUTORIA
Victor E. Reuter, MD,* Pedram Argani, MD,w Ming Zhou, MD, PhD,z Brett Delahunt, MD, FRCPA,y and Members of the ISUP Immunohistochemistry
in Diagnostic Urologic Pathology Group
RESUMO
Primary renal neoplasms comprise multiple distinct
entities, some of which are well understood and others that are
not. It is not uncommon for some of these entities to have
overlapping morphologic features. Their clinical behavior is
varied, ranging from highly malignant to benign, and metastatic
renal cell carcinoma oftentimes enters into the differential diagnosis
of tumors of unknown primary. In this age of personalized
medicine, identifying biomarkers that can better predict
clinical outcome and response to therapy is a pressing need. In
2013 the International Society of Urological Pathology held a
meeting in which best practices recommendations on the use of
immunohistochemical markers in urologic malignancies were
discussed. In this review we make recommendations regarding
immunohistochemical markers that are best suited to aid in establishing
a diagnosis of renal primary, panels of antibodies that
are most useful in classifying renal tumors, and the current
status of prognostic and predictive biomarkers. Although no
prognostic or predictive marker and set of markers have yet to
be validated, ongoing research suggests that this fact is likely to
change in the near future.